TxCell is a spin-off of the French Medical Research Institute (INSERM). Txcell strategy is to develop investigational product in a new class of autologous cellular immunotherapies that are uniquely designed to regulate a patient's own immune system. TxCell Entering now in phase I/IIa clinical trial in Crohn disease and develop Clinical application for Multipe Sclerosis, Rhumathoide Arthritis and orphan's indications.